Tom V, Jose A, Mallick S, Sasidharan A, Pawar R, Somayaji Y
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40063239
DOI: 10.1007/s00210-025-03985-4.
Wu H, Zhang W, Chang J, Wu J, Zhang X, Jia F
Sci Rep. 2025; 15(1):6173.
PMID: 39979377
PMC: 11842742.
DOI: 10.1038/s41598-024-85035-2.
El-Tanani M, Rabbani S, Satyam S, Rangraze I, Wali A, El-Tanani Y
Cancers (Basel). 2025; 17(3).
PMID: 39941751
PMC: 11815874.
DOI: 10.3390/cancers17030382.
Jin L, Lin Z, Jin A
Cytojournal. 2025; 21:67.
PMID: 39917010
PMC: 11801665.
DOI: 10.25259/Cytojournal_43_2024.
Kumar C P, Banumathi , Satyanarayan N, Prasad S, Achur R, Prabhakar B
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39912901
DOI: 10.1007/s00210-025-03830-8.
Engineered CAF-cancer cell hybrid membrane biomimetic dual-targeted integrated platform for multi-dimensional treatment of ovarian cancer.
Yao Y, Zhang J, Huang K, Peng Y, Cheng S, Liu S
J Nanobiotechnology. 2025; 23(1):83.
PMID: 39910555
PMC: 11796236.
DOI: 10.1186/s12951-025-03165-9.
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.
Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S
Sci Rep. 2025; 15(1):4294.
PMID: 39905117
PMC: 11794704.
DOI: 10.1038/s41598-024-82218-9.
MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.
Dong F, Zhou J, Wu Y, Gao Z, Li W, Song Z
Front Cell Dev Biol. 2025; 12:1499111.
PMID: 39882259
PMC: 11774998.
DOI: 10.3389/fcell.2024.1499111.
Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models.
Ye J, Qin S, Hughson A, Hannon G, Vrooman T, Lesch M
Cancers (Basel). 2025; 17(2).
PMID: 39857986
PMC: 11763610.
DOI: 10.3390/cancers17020204.
Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy.
Yan S, Gan Y, Xu H, Piao H
Front Bioeng Biotechnol. 2025; 12():1526612.
PMID: 39845371
PMC: 11750792.
DOI: 10.3389/fbioe.2024.1526612.
Targeting FABP4/UCP2 axis to overcome cetuximab resistance in obesity-driven CRC with drug-tolerant persister cells.
Cheng Y, Chen M, Yadav V, Pikatan N, Fong I, Kuo K
Transl Oncol. 2025; 53:102274.
PMID: 39823981
PMC: 11787020.
DOI: 10.1016/j.tranon.2025.102274.
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial Teams.
Cosgrove P, Bild A, Dellinger T, Badie B, Portnow J, Nath A
J Clin Med. 2025; 13(24.
PMID: 39768430
PMC: 11677125.
DOI: 10.3390/jcm13247507.
The role of mitochondria in aging, cell death, and tumor immunity.
Wang Q, Yuan Y, Liu J, Li C, Jiang X
Front Immunol. 2025; 15:1520072.
PMID: 39763653
PMC: 11701224.
DOI: 10.3389/fimmu.2024.1520072.
A comprehensive analysis of vasculogenic mimicry related genes to predict the survival rate of HCC and its influence on the tumor microenvironment.
Wang J, Gao R, Qi J, Xing Y, Hong B, Wang H
Front Genet. 2025; 15:1437715.
PMID: 39748947
PMC: 11693674.
DOI: 10.3389/fgene.2024.1437715.
Bioinformatics-Based Construction of Immune-Related microRNA and mRNA Prognostic Models for Hepatocellular Carcinoma.
Chen Y, Yin D, Feng X, He S, Zhang L, Chen D
Cancer Manag Res. 2025; 16:1793-1811.
PMID: 39741650
PMC: 11687126.
DOI: 10.2147/CMAR.S482688.
Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.
Singh D, Haque S, Kim Y, Han I, Yadav D
Front Immunol. 2024; 15:1455211.
PMID: 39720730
PMC: 11666570.
DOI: 10.3389/fimmu.2024.1455211.
Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.
He X, Deng H, Liu W, Hu L, Tan X
Curr Treat Options Oncol. 2024; 25(12):1615-1633.
PMID: 39633237
DOI: 10.1007/s11864-024-01279-0.
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y
Mol Cancer. 2024; 23(1):261.
PMID: 39574178
PMC: 11580516.
DOI: 10.1186/s12943-024-02165-x.
Bioinformatics combined with network pharmacology and experimental validation to identify key biomarkers of hepatocellular carcinoma and corresponding compounds in Radix Astragali and Pueraria Mirifica.
Li M, Liu B, Xian M, Wang S, Liu P
Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39549064
DOI: 10.1007/s00210-024-03597-4.
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.
Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T
J Biol Chem. 2024; 300(12):107994.
PMID: 39547513
PMC: 11714729.
DOI: 10.1016/j.jbc.2024.107994.